膠質瘤治療市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病、治療類型、分級、最終用戶、地區和競爭格局分類，2021-2031年

全球膠質母細胞瘤治療市場預計將從 2025 年的 93.4 億美元成長到 2031 年的 147.8 億美元，複合年成長率為 7.95%。

此領域涵蓋針對神經膠質細胞來源的原發性腦腫瘤的治療性介入，包括手術切除、放射線治療、化療和標靶免疫療法等策略。市場成長趨勢的主要促進因素是全球人口老化，老年人罹患中樞神經系統惡性腫瘤的風險較高，以及此類疾病整體盛行率的上升。此外，醫療基礎設施的進步和先進的診斷成像治療方法。

根據美國中樞神經系統腫瘤登記處的數據，到2024年，膠質瘤將佔所有原發性腦腫瘤和其他中樞神經系統腫瘤的約22.9%。儘管疾病負擔如此沉重，但市場仍面臨一個重大障礙：血腦障壁。血腦屏障嚴重限制了治療藥物向腫瘤部位的輸送。這一生理屏障阻礙了有效全身治療方法的研發，常常導致臨床試驗的高失敗率，阻礙了市場的快速擴張。

市場促進因素

強大的臨床研發管線，包括新型免疫療法和生物目標，正成為市場擴張的重要催化劑，製藥公司也日益重視IDH變異抑制劑以應對抗藥性機制。能夠延緩疾病進展的標靶治療獲得監管批准是一項重大進展。例如，2024年8月，施維雅宣布FDA核准VORANIGO上市。在INDIGO III期臨床試驗中，與安慰劑相比，borasidenib可使2級IDH突變型膠質母細胞瘤患者的腫瘤進展或死亡風險降低61%。這些臨床里程碑證明了精準醫療的有效性，並刺激了對該治療領域的進一步投資。

同時，非侵入性治療方法，特別是腫瘤電場療法（TTF）的技術創新，正在透過提高存活率來改變治療模式。研發人員正在將這些治療方法與標準放射線治療結合，以增強局部控制。根據Novocure公司於2024年5月發表的METIS III期臨床試驗結果，接受腫瘤電場療法治療的患者顱內進展的中位數時間為21.9個月，顯著長於對照組的11.3個月。鑑於這些惡性腫瘤的高死亡率，這些進展至關重要。美國癌症協會估計，2024年美國將有約18,760人死於腦部和其他神經系統腫瘤，凸顯了發展新型治療方法的必要性。

市場挑戰

血腦障壁是全球膠質母細胞瘤治療市場面臨的一大障礙，因為它從物理層面阻止了治療藥物到達腫瘤部位。這種生理防禦機制阻礙了大多數全身性藥物的通過，使藥物製劑的研發變得複雜，並需要耗費巨資進行研發。因此，開發平臺充滿障礙，延緩了進展，並增加了新治療方法上市的成本。

這一障礙導致臨床試驗中較高的脫落率，直接阻礙了市場成長。由於藥物輸送不足，療效難以證實，限制了商業化機會，並阻礙了持續投資。根據美國腦腫瘤學會統計，截至2024年，僅有四種藥物獲得FDA核准用於治療膠質母細胞瘤。可上市產品的匱乏限制了行業相關人員的產生收入機會，並凸顯了血腦障壁如何透過阻礙新治療方法的商業化，有效地抑制了該領域的擴張。

市場趨勢

嵌合體抗原受體（CAR）T細胞療法的進展正在從根本上改變固態腫瘤異質性的挑戰。研究人員目前正在設計能夠同時針對多種抗原（例如EGFRvIII和野生型EGFR）的T細胞，以期阻止過去導致治療失敗的抗原逃脫機制。這種從單靶點到多標靶細胞工程的轉變，正為復發患者帶來前所未有的療效。例如，2024年3月，麻省總醫院報告稱，接受新型CAR-TEAM細胞治療的患者療效迅速，其中一名患者在治療69天后腫瘤面積縮小了60.7%。這顯示細胞療法正逐漸成為治療方法中樞神經系統惡性腫瘤的有效方法。

同時，能夠穿過血腦障壁的新型藥物遞送系統的研發正在克服該領域最頑固的生理障礙。為了提高全身性細胞毒性藥物的療效，研發人員正在檢驗植入式超音波技術。這項技術能夠暫時破壞血腦障壁，使化療藥物達到治療濃度，進而到達腦實質。這種方法使得一些先前因顱內滲透性差而受限的藥物得以有效再利用。根據Carsela公司於2024年3月公佈的SonoCloud-9 I/II期臨床試驗的積極結果，接受Carboplatin聯合該設備治療的複發性膠質母細胞瘤患者的一年生存率達到了58%。與傳統對照組相比，這是一個顯著的進步，也標誌著器械與藥物聯合治療策略取得了進展。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球膠質瘤治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 疾病特異性資訊（星狀細胞瘤、少突星狀細胞瘤、少突膠質細胞瘤）
  • 治療方法（手術、化療、放射線治療、其他）
  • 依分化程度（分化不良、分化良好）
  • 依最終使用者（醫院/診所、門診手術中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美膠質瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲膠質瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區膠質瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲膠質瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲膠質瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球膠質瘤治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co. KGaA
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Glioma Treatment Market is projected to expand from a valuation of USD 9.34 Billion in 2025 to USD 14.78 Billion by 2031, reflecting a CAGR of 7.95%. This sector encompasses therapeutic interventions for primary brain tumors derived from glial cells, employing strategies such as surgical resection, radiation therapy, chemotherapy, and targeted immunotherapies. The market's upward trajectory is fundamentally fueled by an aging global population that exhibits higher susceptibility to central nervous system malignancies, alongside a general increase in the prevalence of these conditions. Additionally, advancements in healthcare infrastructure and superior diagnostic imaging technologies are enabling earlier detection, thereby driving the demand for both standard and innovative therapeutic regimens.

According to data from the Central Brain Tumor Registry of the United States, gliomas represented approximately 22.9% of all primary brain and other central nervous system tumors in 2024. Despite this significant disease burden, the market encounters a major impediment in the form of the blood-brain barrier, which severely limits the delivery of therapeutic agents to the tumor site. This physiological obstacle hampers the development of effective systemic treatments and frequently results in high failure rates during clinical trials, consequently preventing rapid market expansion.

Market Driver

A robust clinical pipeline featuring novel immunotherapies and targeted biologics serves as a primary catalyst for market expansion, with pharmaceutical companies increasingly prioritizing IDH-mutant inhibitors to address resistance mechanisms. A pivotal development involves the regulatory success of targeted therapies capable of delaying disease progression. For instance, Servier announced in August 2024 via their 'FDA Approves VORANIGO' release that the Phase 3 INDIGO clinical trial showed vorasidenib reduced the risk of tumor progression or death by 61% in patients with Grade 2 IDH-mutant glioma compared to a placebo. Such clinical milestones validate the efficacy of precision medicine and encourage further investment into expanding the therapeutic landscape.

Simultaneously, technological innovations in non-invasive modalities, specifically Tumor Treating Fields, are altering treatment paradigms by extending survival rates. Developers are integrating these fields with standard radiotherapy to enhance local control. As reported by Novocure in May 2024 regarding the 'METIS Phase 3 Clinical Trial,' patients treated with Tumor Treating Fields therapy demonstrated a median time to intracranial progression of 21.9 months, significantly outperforming the 11.3 months observed in the control arm. These advancements are critical given the high mortality rates associated with these malignancies; the American Cancer Society estimated that in 2024, approximately 18,760 individuals in the United States would die from brain and other nervous system tumors, underscoring the need for these evolving interventions.

Market Challenge

The blood-brain barrier acts as a severe restriction on the Global Glioma Treatment Market by physically blocking therapeutic agents from reaching the tumor site. This physiological defense mechanism prevents the passage of most systemic drugs, complicating drug formulation and necessitating expensive research efforts. Consequently, the development pipeline is fraught with obstacles that delay progress and inflate the cost of bringing new therapies to market.

This impediment directly stunts market growth by contributing to high attrition rates in clinical trials. The inability to demonstrate efficacy due to poor drug delivery results in a sparse commercial landscape, discouraging sustained financial investment. According to the National Brain Tumor Society, in 2024, there were only four FDA-approved drugs available for the treatment of glioblastoma. This low number of marketable products limits revenue generation opportunities for industry players and highlights how the blood-brain barrier effectively bottlenecks the expansion of the sector by preventing the successful commercialization of novel treatments.

Market Trends

The advancement of Chimeric Antigen Receptor (CAR) T-Cell Therapies is fundamentally reshaping the clinical landscape by addressing the challenge of solid tumor heterogeneity in glioblastoma. Researchers are now engineering T-cells capable of targeting multiple antigens simultaneously, such as EGFRvIII and wild-type EGFR, to prevent the antigen escape mechanisms that historically caused treatment failure. This shift from single-target to multi-target cellular engineering is yielding unprecedented responses in patients with recurrent disease; for example, Massachusetts General Hospital reported in March 2024 that patients treated with novel CAR-TEAM cells exhibited rapid responses, with one participant demonstrating a 60.7% decrease in tumor cross-sectional area by day 69, indicating that cellular therapies are becoming a viable modality for central nervous system malignancies.

Simultaneously, the development of novel delivery systems to cross the blood-brain barrier is overcoming the sector's most persistent physiological impediment. To enhance the efficacy of systemic cytotoxic agents, developers are validating implantable ultrasound technologies that temporarily disrupt the blood-brain barrier, allowing therapeutic concentrations of chemotherapy to reach the brain parenchyma. This approach effectively repurposes existing drugs that were previously limited by poor intracranial penetration. According to Carthera's March 2024 announcement regarding positive results from the Phase I/II clinical trial of SonoCloud-9, patients with recurrent glioblastoma who received carboplatin in combination with the device achieved a one-year overall survival rate of 58%, a substantial improvement over historical controls, signifying a move toward device-drug combination strategies.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co. KGaA
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

Report Scope

In this report, the Global Glioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glioma Treatment Market, By Disease

• Astrocytoma
• Oligoastrocytoma
• Oligodendroglioma

Glioma Treatment Market, By Treatment Type

• Surgery
• Chemotherapy
• Radiation Therapy
• Others

Glioma Treatment Market, By Grade

• Low Grade
• High Grade

Glioma Treatment Market, By End user

• Hospital & Clinics
• Ambulatory Surgical Centers
• Others

Glioma Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Glioma Treatment Market.

Available Customizations:

Global Glioma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glioma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Astrocytoma, Oligoastrocytoma, Oligodendroglioma)
  • 5.2.2. By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Others)
  • 5.2.3. By Grade (Low Grade, High Grade)
  • 5.2.4. By End user (Hospital & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Glioma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Treatment Type
  • 6.2.3. By Grade
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Glioma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Grade
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Glioma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Grade
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Glioma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Grade
      • 6.3.3.2.4. By End user

7. Europe Glioma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Treatment Type
  • 7.2.3. By Grade
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Glioma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Grade
      • 7.3.1.2.4. By End user
  • 7.3.2. France Glioma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Grade
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Glioma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Grade
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Glioma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Grade
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Glioma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Grade
      • 7.3.5.2.4. By End user

8. Asia Pacific Glioma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Treatment Type
  • 8.2.3. By Grade
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Glioma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Grade
      • 8.3.1.2.4. By End user
  • 8.3.2. India Glioma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Grade
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Glioma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Grade
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Glioma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Grade
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Glioma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Grade
      • 8.3.5.2.4. By End user

9. Middle East & Africa Glioma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Treatment Type
  • 9.2.3. By Grade
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Glioma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Grade
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Glioma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Grade
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Glioma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Grade
      • 9.3.3.2.4. By End user

10. South America Glioma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Treatment Type
  • 10.2.3. By Grade
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Glioma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Grade
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Glioma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Grade
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Glioma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Grade
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Glioma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Arbor Pharmaceuticals LLC
• 15.3. Merck & Co. KGaA
• 15.4. Sun Pharmaceutical Industries Ltd
• 15.5. Amgen Inc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Pfizer Inc
• 15.8. Amneal Pharmaceuticals Inc
• 15.9. Karyopharm Therapeutics Inc
• 15.10. Biocon Ltd

16. Strategic Recommendations

17. About Us & Disclaimer